Original articlesSyntheses and biological evaluation of 18F-labeled 3-(1-benzyl-piperidin-4-yl)-1-(1-methyl-1H-indol-3-yl)propan-1-ones for in vivo mapping of acetylcholinesterase
Review articleOpen access
Abstract:

AbstractWe synthesized novel 18F-labeled acetylcholinesterase (AChE) inhibitors, 3-[1-(3- and 4-[18F]fluoromethylbenzyl)piperidin-4-yl]-1-(1-methyl-1H-indol-3-yl)propan-1-ones ([18F]1 and [18F]2) and 3-[1-(4-[18F]fluorobenzyl)piperidin-4-yl]-1-(1-methyl-1H-indol-3-yl)propan-1-one ([18F]3) in high yields (decay-corrected, 25%–40%) and with high effective specific activities (>37 GBq/μmol). Tissue distribution studies of the [18F]1 and the [18F]3 in mice showed the nonspecific bindings in brain regions, with metabolic defluorination of the [18F]1. The result suggests that these radioligands may not be suitable agents for in vivo mapping of AChE, despite their potent in vitro anti-AChE activities.

Request full text

References (0)

Cited By (0)

No reference data.
No citation data.
Advertisement
Join Copernicus Academic and get access to over 12 million papers authored by 7+ million academics.
Join for free!